Equillium Stock

Equillium Book Value per Share

The Book Value per Share of Equillium (EQ) as of Aug 20, 2026 is 0.47 USD. In the previous year, Book Value per Share was 0.31 USD — a change of 50.03% (higher).

Book Value per Share

0.47USD

YoY

50.03%

Last updated:

Book Value per Share of Equillium is 2026 0.47 USD. Book Value per Share of Equillium was 2025 0.31 USD. It decreases by 50.03% higher compared to the previous year.
Access this data via the Eulerpool API

Equillium Stock analysis

What does Equillium do? Equillium Inc is an emerging biotechnology company specializing in the research and development of therapies for the treatment of inflammatory and autoimmune diseases. The company was founded in 2017 by a group of experienced biotech entrepreneurs who aim to develop innovative and effective treatment methods to improve patients' quality of life. Equillium's business model focuses on the discovery and development of new therapies based on the modulation of the CD6 signaling pathway, a central regulator of the immune system. Equillium's technology aims to modulate the immune system to suppress an inflammatory response associated with autoimmune and other inflammatory diseases. The company collaborates closely with leading university research laboratories and experts in the field to develop effective therapies. Equillium targets a wide range of disease areas, including autoimmune diseases such as lupus, psoriasis, and Crohn's disease. The company has also developed a program to treat COVID-19, aiming to reduce the immune-mediated inflammatory response associated with severe cases of COVID-19. Equillium's product portfolio includes EQ001, a monoclonal antibody used for the treatment of lupus and other autoimmune diseases. EQ001 blocks the CD6 signaling pathway, thereby reducing inflammatory responses that attack healthy tissues in the body. The company is also working on developing a novel platform technology to explore additional therapy options based on the CD6 signaling pathway. Equillium has a strong funding base and is supported by some of the most renowned biotech investors. The company has a comprehensive pipeline of potential therapies that are intended to address a variety of indications in the future. Overall, Equillium's advanced biotechnological research and development have contributed to the discovery of new and effective ways to treat inflammatory and autoimmune diseases. The company is well-positioned to expand in this area of medicine and improve therapy options for patients worldwide. Equillium is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Equillium stock

Book Value per Share of Equillium is 0.47 USD in 2026.

Book Value per Share of Equillium changed from 0.31 USD to 0.47 USD, representing a 50.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Equillium since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

Balance Sheet — Equillium

All Key Metrics — Equillium